45-47-Clinigene-Hester Biosciences-Max Neeman International
15 June 2010 | News
45
Clinigene
Clinigene International, the clinical research arm of biotech major Biocon, has grossed Rs 39 crore as revenue for the fiscal year ended March 31, 2010. Clinigene is a full-service CRO that partners global pharma and biotech companies in their clinical development programs. Established in 2000, Clinigene became India’s first CAP accredited Central Laboratory followed by NABL accreditation in 2003. Clinigene’s services now span a broad spectrum of activities—human pharmacology, clinical operations, clinical development, clinical data management and biostatistics, regulatory, bioanalytical research and central laboratory services supporting early phase through late-phase clinical development programs. All activities are carried out in strict compliance with regulatory and ICH GCP requirements. Its comprehensive investigator database and expertise in many therapeutic areas helps in providing faster patient recruitment, cost competitive trials, yet world-class clinical support.
46
Hester Biosciences
Veterinary vaccines manufacturer, Hester Biosciences has registered an annual turnover of Rs 37.53 crore in fiscal 2009-2010. Located near Ahmedabad, Hester is ISO 9001-2000 and GMP certified. The product range includes 39 types of poultry vaccines, 28 types of live and 11 types of inactivated poultry vaccines. Hester has a state-of-the-art facility to produce live and inactivated veterinary vaccines. It has a capacity to manufacture over five billion doses of animal vaccines, with the current capacity utilization at 35 percent.
Apart from export of vaccines, Hester imports one vaccine from the US. Exports are currently done to three countries and registration is pending in over 10 countries. Besides marketing its own vaccines, Hester represent companies like Merial, US and Biopharm, Czech Republic for poultry vaccines; and Synbiotics, US for animal diagnostic kits for the Indian market. Hester currently is also looking at establishing a base either in the US or Europe as a means to achieve its global ambitions.
47
Max Neeman International
The accumulated revenue for Indovax for the fiscal 2009-2010 is Rs 36.94. Indovax has been engaged in the production of poultry biologicals since 1991. Its product portfolio consists of viral and inactivated vaccines. Some of them are Newcastle vaccine (Ranikhet vaccine), Gumboro vaccine (IBD), Marek’s vccine, infectious bronchitis vaccine, fowl pox vaccine, fowl cholera vaccine and infectious coryza vaccine. It has a modern state-of-the-art facility spread over 14 acres in a
completely poultry-free zone. The company has been focusing on introducing a new product every six months.
Indovax in joint venture with Gezondheidsdienst voor Dieren BV, a Dutch entity and one of the world’s largest veterinary diagnostic laboratories are executing a collaborative biotechnology project to produce SPF Embryonated eggs and Diagnostic reagents. The Project under execution in Himachal Pradesh is supported by the Dutch Government.
Clinigene
| CMD | Dr Kiran Mazumdar Shaw |
 |
| Business | Clinical research |
|
| Start-up Year | 2000 | |
| Biotech Revenue | Rs 39 crore | |
| Address | Clinigene House, Tower 1, Semicon Park, Electronic
City, Phase II, Bangalore-560100 |
|
| Tel | +91-80-28082728 | |
| Fax | +91-80-28522989 |
|
| Website | www.clinigeneintl.com |
Clinigene International, the clinical research arm of biotech major Biocon, has grossed Rs 39 crore as revenue for the fiscal year ended March 31, 2010. Clinigene is a full-service CRO that partners global pharma and biotech companies in their clinical development programs. Established in 2000, Clinigene became India’s first CAP accredited Central Laboratory followed by NABL accreditation in 2003. Clinigene’s services now span a broad spectrum of activities—human pharmacology, clinical operations, clinical development, clinical data management and biostatistics, regulatory, bioanalytical research and central laboratory services supporting early phase through late-phase clinical development programs. All activities are carried out in strict compliance with regulatory and ICH GCP requirements. Its comprehensive investigator database and expertise in many therapeutic areas helps in providing faster patient recruitment, cost competitive trials, yet world-class clinical support.
46
Hester Biosciences
| CEO & MD | Rajiv Gandhi |
 |
| Business | Manufacturing of Poultry Vaccines |
|
| Start-up Year | 1997 | |
| Biotech Revenue | Rs 37.53 crore |
|
| Address | 16/10 Devendra Society, Naranpura, Ahmedabad-380013 |
|
| Tel | +91-79-27680476 | |
| Fax | +91-79-27682250 | |
| Website | www.hesterbiosciences.co.in |
Veterinary vaccines manufacturer, Hester Biosciences has registered an annual turnover of Rs 37.53 crore in fiscal 2009-2010. Located near Ahmedabad, Hester is ISO 9001-2000 and GMP certified. The product range includes 39 types of poultry vaccines, 28 types of live and 11 types of inactivated poultry vaccines. Hester has a state-of-the-art facility to produce live and inactivated veterinary vaccines. It has a capacity to manufacture over five billion doses of animal vaccines, with the current capacity utilization at 35 percent.
Apart from export of vaccines, Hester imports one vaccine from the US. Exports are currently done to three countries and registration is pending in over 10 countries. Besides marketing its own vaccines, Hester represent companies like Merial, US and Biopharm, Czech Republic for poultry vaccines; and Synbiotics, US for animal diagnostic kits for the Indian market. Hester currently is also looking at establishing a base either in the US or Europe as a means to achieve its global ambitions.
47
Max Neeman International
| MD | Deepak Kapoor |  |
| Business | Production and marketing of poultry biologicals |
|
| Start-up Year | 1991 | |
| Biotech Revenue | Rs 36.94 crore |
|
| Address | Corporate Heights, SCO-24, Sector-14, Gurgaon-122 001 |
|
| Tel | +91-124-22315045 | |
| Fax | - | |
| Website | www.indovax.com |
The accumulated revenue for Indovax for the fiscal 2009-2010 is Rs 36.94. Indovax has been engaged in the production of poultry biologicals since 1991. Its product portfolio consists of viral and inactivated vaccines. Some of them are Newcastle vaccine (Ranikhet vaccine), Gumboro vaccine (IBD), Marek’s vccine, infectious bronchitis vaccine, fowl pox vaccine, fowl cholera vaccine and infectious coryza vaccine. It has a modern state-of-the-art facility spread over 14 acres in a
completely poultry-free zone. The company has been focusing on introducing a new product every six months.
Indovax in joint venture with Gezondheidsdienst voor Dieren BV, a Dutch entity and one of the world’s largest veterinary diagnostic laboratories are executing a collaborative biotechnology project to produce SPF Embryonated eggs and Diagnostic reagents. The Project under execution in Himachal Pradesh is supported by the Dutch Government.
